All In Biotech

Drug Trial Radar · NCT03973047

Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

A Phase 1, Randomized Study to Evaluate the Rate of Nausea in Healthy Premenopausal Female Subjects Treated With a Single Dose of Bremelanotide Alone or With Zofran

Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

228

Actual

Start

Jun 17, 2019

Primary completion

Jul 19, 2019

Study completion Jul 20, 2019

Sponsor

Lead sponsor
AMAG Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized study to evaluate the rate of nausea in healthy premenopausal study participants following a single dose of BMT with or without a single 8 mg po dose of Zofran given 30 minutes before BMT dosing.

Conditions

  • Nausea

Interventions

  • BremelanotideDrug

    Sterile aqueous solution for injection, provided as an autoinjector pen

  • ZofranDrug

    8 mg tablet (over-encapsulation in a capsule)

  • PlaceboDrug

    capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent nausea following BMT with or without concomitant use of Zofran.Time frame: 2 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Serrvices, LLC

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.